GB0213622D0 - Vaccine Corporation - Google Patents

Vaccine Corporation

Info

Publication number
GB0213622D0
GB0213622D0 GBGB0213622.4A GB0213622A GB0213622D0 GB 0213622 D0 GB0213622 D0 GB 0213622D0 GB 0213622 A GB0213622 A GB 0213622A GB 0213622 D0 GB0213622 D0 GB 0213622D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
corporation
vaccine corporation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0213622.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FINLAY INST
GlaxoSmithKline Biologicals SA
Original Assignee
FINLAY INST
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FINLAY INST, GlaxoSmithKline Biologicals SA filed Critical FINLAY INST
Priority to GBGB0213622.4A priority Critical patent/GB0213622D0/en
Publication of GB0213622D0 publication Critical patent/GB0213622D0/en
Priority to CA002488782A priority patent/CA2488782A1/en
Priority to RU2005100509/13A priority patent/RU2005100509A/ru
Priority to KR1020047019991A priority patent/KR20050049431A/ko
Priority to AU2003236734A priority patent/AU2003236734A1/en
Priority to EP03735599A priority patent/EP1565211A2/en
Priority to MXPA04012568A priority patent/MXPA04012568A/es
Priority to CL200301192A priority patent/CL2003001192A1/es
Priority to CNB038162822A priority patent/CN100387298C/zh
Priority to JP2004512791A priority patent/JP2005531614A/ja
Priority to BR0311777-4A priority patent/BR0311777A/pt
Priority to US10/529,064 priority patent/US20060110412A1/en
Priority to NZ560766A priority patent/NZ560766A/en
Priority to PCT/EP2003/006094 priority patent/WO2003105890A2/en
Priority to PE2003000583A priority patent/PE20040562A1/es
Priority to UY27843A priority patent/UY27843A1/es
Priority to ARP030102096A priority patent/AR040204A1/es
Priority to ZA200409547A priority patent/ZA200409547B/en
Priority to CU20040285A priority patent/CU23552A1/es
Priority to NO20050132A priority patent/NO20050132L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0213622.4A 2002-06-13 2002-06-13 Vaccine Corporation Ceased GB0213622D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition
CNB038162822A CN100387298C (zh) 2002-06-13 2003-06-10 疫苗组合物
BR0311777-4A BR0311777A (pt) 2002-06-13 2003-06-10 Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
KR1020047019991A KR20050049431A (ko) 2002-06-13 2003-06-10 다가의 메닝고코쿠스 외부 멤브레인 소낭의 혼합물을포함하는 백신
AU2003236734A AU2003236734A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
EP03735599A EP1565211A2 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
MXPA04012568A MXPA04012568A (es) 2002-06-13 2003-06-10 Vacuna que comprende mezclas de vesiculas de membrana externa meningococales multivalentes.
CL200301192A CL2003001192A1 (es) 2002-06-13 2003-06-10 Composicion inmunogenica meningococica multivalente, de vesiculas de membrana externa, que comprende una vesicula con actividad homologa de un subserotipo prevalente en un pais y otra vesicula con actividad heterologa, que tiene disminuida una protei
CA002488782A CA2488782A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles
JP2004512791A JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物
RU2005100509/13A RU2005100509A (ru) 2002-06-13 2003-06-10 Вакцинная композиция
US10/529,064 US20060110412A1 (en) 2002-06-13 2003-06-10 Vaccine composition
NZ560766A NZ560766A (en) 2002-06-13 2003-06-10 Vaccine composition comprising mixtures of multivalent meningococcal outer membrane vesicles
ARP030102096A AR040204A1 (es) 2002-06-13 2003-06-11 Composicion de vacuna meningococica multivalente
PE2003000583A PE20040562A1 (es) 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes
UY27843A UY27843A1 (es) 2002-06-13 2003-06-11 Composicion de vacuna
ZA200409547A ZA200409547B (en) 2002-06-13 2004-11-25 Vaccine comprins mixtures of multivalent menigococcal outer membrane vesciles
CU20040285A CU23552A1 (es) 2002-06-13 2004-12-10 Composición vacunal
NO20050132A NO20050132L (no) 2002-06-13 2005-01-11 Vaksinesammensetning som omfatter blanding av multivalente meningokokk yttermembran vesikler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (1)

Publication Number Publication Date
GB0213622D0 true GB0213622D0 (en) 2002-07-24

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0213622.4A Ceased GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Country Status (20)

Country Link
US (1) US20060110412A1 (enExample)
EP (1) EP1565211A2 (enExample)
JP (1) JP2005531614A (enExample)
KR (1) KR20050049431A (enExample)
CN (1) CN100387298C (enExample)
AR (1) AR040204A1 (enExample)
AU (1) AU2003236734A1 (enExample)
BR (1) BR0311777A (enExample)
CA (1) CA2488782A1 (enExample)
CL (1) CL2003001192A1 (enExample)
CU (1) CU23552A1 (enExample)
GB (1) GB0213622D0 (enExample)
MX (1) MXPA04012568A (enExample)
NO (1) NO20050132L (enExample)
NZ (1) NZ560766A (enExample)
PE (1) PE20040562A1 (enExample)
RU (1) RU2005100509A (enExample)
UY (1) UY27843A1 (enExample)
WO (1) WO2003105890A2 (enExample)
ZA (1) ZA200409547B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1855715B1 (en) 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
BRPI0907010A2 (pt) * 2008-02-01 2015-07-07 Sanofi Pasteur Ltd Análise para o diagnóstico de streptococcus pneumoniae
KR101208778B1 (ko) 2008-03-03 2012-12-05 노파르티스 아게 Ｔｌｒ 활성 조정제로서의 화합물 및 조성물
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
TR201802380T4 (tr) 2009-06-10 2018-03-21 Glaxosmithkline Biologicals Sa Benzonaftiridin içeren aşılar.
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011043538A2 (ko) * 2009-10-08 2011-04-14 주식회사이언메딕스 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
JP5894083B2 (ja) * 2009-12-22 2016-03-23 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 免疫原性組成物
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
CN102905703B (zh) 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
JP2023546665A (ja) * 2020-10-23 2023-11-07 オームヴァックス，インコーポレイテッド． 淋菌（Ｎｅｉｓｓｅｒｉａ Ｇｏｎｏｒｒｈｏｅａｅ）に対するワクチン接種のための組成物及び方法
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
JP5511117B2 (ja) * 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン

Also Published As

Publication number Publication date
ZA200409547B (en) 2006-07-26
CA2488782A1 (en) 2003-12-24
WO2003105890A3 (en) 2004-03-25
CL2003001192A1 (es) 2005-01-07
CN100387298C (zh) 2008-05-14
CN1668329A (zh) 2005-09-14
AU2003236734A1 (en) 2003-12-31
JP2005531614A (ja) 2005-10-20
KR20050049431A (ko) 2005-05-25
BR0311777A (pt) 2005-03-29
CU23552A1 (es) 2010-07-20
AR040204A1 (es) 2005-03-16
UY27843A1 (es) 2003-12-31
PE20040562A1 (es) 2004-10-19
RU2005100509A (ru) 2006-06-10
NO20050132L (no) 2005-02-11
MXPA04012568A (es) 2005-09-21
NO20050132D0 (no) 2005-01-11
US20060110412A1 (en) 2006-05-25
EP1565211A2 (en) 2005-08-24
WO2003105890A2 (en) 2003-12-24
NZ560766A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0226722D0 (en) Vaccine
GB0202901D0 (en) Novel vaccine
GB0225788D0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0209878D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
PL376534A1 (pl) Szczepionka
IL173921A0 (en) Vaccine
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0305793D0 (en) Vaccine
AU2003237701A8 (en) Vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0220212D0 (en) Vaccine
GB0209724D0 (en) Vaccine
GB0228716D0 (en) Vaccine
GB0206054D0 (en) Vaccine
GB0206575D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)